It is revealed that patients with ER+/HER2+ compared with ER-/HER2+ breast cancers may actually benefit more from drugs that inhibit the PI3K/AKT molecular pathway
http://en.wikipedia.org/wiki/ErbB
Estrogen Receptor Status of HER2+ Breast Cancer Correlates With Response to Anti-HER Therapies. ScienceDaily (May 6, 2010)[1]
http://www.sciencedaily.com/releases/2010/05/100506112557.htm
http://www.pnas.org/content/107/22/10208.short
No comments:
Post a Comment